Structure: Structural insights into the assembly and regulation of 2′-O RNA methylation by SARS-CoV-2 nsp16/nsp10 (Gupta Lab)

  • SARS-CoV-2 nsp16/nsp10 oligomerizes on capped mRNA for efficient 2′-O methylation
  • An aromatic zipper in nsp16 modulate oligomerization and methylation
  • N-terminus of nsp10 is required for efficient 2′-O methylation
  • A nucleotide-binding pocket on the backside of nsp16 modulates the 2′-O methylation

Summary

2′-O-ribose methylation of viral RNA’s first transcribed base (adenine or A1 in SARS-CoV-2) mimics host RNAs and subverts the innate immune response. How nsp16, with partner nsp10, assembles on the 5′-end of SARS-CoV-2 mRNA to methylate A1 is not fully understood. We present a ∼2.4 Å crystal structure of the heterotetrameric complex formed by the cooperative assembly of two nsp16/nsp10 heterodimers with one 10-mer Cap-1 RNA (product) bound to each. An aromatic zipper-like motif in nsp16 and the N-terminal regions of nsp10 and nsp16 orchestrate oligomeric assembly for efficient methylation. The front catalytic pocket of nsp16 stabilizes the upstream portion of the RNA while downstream RNA remains unresolved, likely due to flexibility. An inverted nsp16 dimer extends the positively charged surface for longer RNA to influence catalysis. Additionally, a non-specific nucleotide-binding pocket on the backside of nsp16 plays a critical role in catalysis, contributing to enzymatic activity.
1-s2.0-S0969212625001066-fx1_lrg
Categories:

Since 2004, UT Health San Antonio, Greehey Children’s Cancer Research Institute’s (Greehey CCRI) mission has been to advance scientific knowledge relevant to childhood cancer, contribute to understanding its causes, and accelerate the translation of knowledge into novel therapies. Greehey CCRI strives to have a national and global impact on childhood cancer by discovering, developing, and disseminating new scientific knowledge. Our mission consists of three key areas — research, clinical, and education.

 

Stay connected with the Greehey CCRI on FacebookTwitterLinkedIn, and Instagram.